SPRC on Nasdaq

SciSparc

Logo: scisparc.com3

SciSparc is a pharmaceutical company.1 Its shares trade on Nasdaq under the symbol SPRC.1

Price unavailable

Last updated Oct 20, 2026.

Overview

Compare with IGC Pharma, Inc., Vistagen Therapeutics, Inc. or BeyondSpring Inc., or pick any stock.

  • TickerSPRC on Nasdaq1
  • Industrypharmaceutical industry1
  • HeadquartersL31
  • Websitescisparc.com
  • Incorporated inIsrael4
  • Business address20 Raul Wallenberg Street, Tower A, Tel Aviv, L3 69719164
  • Filer categoryNon-accelerated filer4
  • Legal formOther

See how the biggest companies compare on our leaderboards

Treatment was given in a dose titration regimen with a maximum dose of SCI-110 consisting of 10mg dronabinol and 800mg CannAmide™.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2024

38.7%Gross margin6
-560.2%Operating margin6
-572.1%Net margin6
-54.6%Revenue growth, 20246
-83.6%Return on equity6

Where the money goes

Where each dollar of revenue went, fiscal 2024

  • Cost of revenue28¢$800.0K
  • Research and development59¢$1.7M
  • Interest12¢$353.0K
  • Income tax0¢$14.0K

Out of $1.3M in revenue.6 The company lost money this year.

Financial statements

Revenue6$1.3M in 2024−3% since 2022
0$1.0M$2.0M$3.0M2022: $1.3M$1.3M20222023: $2.9M$2.9M2023+114%2024: $1.3M$1.3M2024−55%
Gross profit6$506.0K in 2024−51% since 2022
0$1.0M$2.0M$3.0M2022: $1.0M$1.0M20222023: $2.2M$2.2M2023+114%2024: $506.0K$506.0K2024−77%
Operating income789106-$7.3M in 2024+1% since 2018
-$10.0M-$7.5M-$5.0M-$2.5M02018: -$7.2M-$7.2M20182019: -$4.1M-$4.1M2019−43%2020: -$3.3M-$3.3M2020−20%2021: -$5.8M-$5.8M2021+75%2022: -$8.3M-$8.3M2022+44%2023: -$6.8M-$6.8M2023−18%2024: -$7.3M-$7.3M2024+7%
Net income7106-$7.5M in 2024−17% since 2018
-$10.0M-$7.5M-$5.0M-$2.5M02018: -$8.9M-$8.9M20182019: -$4.7M-$4.7M2019−48%2020: -$3.5M-$3.5M2020−25%2021: -$5.8M-$5.8M2021+64%2022: -$2.6M-$2.6M2022−55%2023: -$5.9M-$5.9M2023+127%2024: -$7.5M-$7.5M2024+27%

Every line of the income statement as filed: the last 3 fiscal years, latest first.11

Period ending2025-12-312024-12-312023-12-31
Revenues$856.0K$1.3M$2.9M
Cost of revenues$225.0K$800.0K$683.0K
Gross profit$631.0K$506.0K$2.2M
Research and development expenses$2.1M$1.7M$1.6M
Sales and marketing$912.0K$1.5M$2.5M
Impairment of intangible assets$115.0K$1.3M$1.0M
General and administrative expenses$6.4M$4.5M$3.8M
Other income, net-$490.0K-$1.3M
Operating loss$8.4M$7.3M$6.8M
Equity losses of an associate$500.0K$429.0K$210.0K
Gain from sale of an associate-$2.2M
Finance income-$2.3M-$612.0K-$2.2M
Finance expenses$8.2M$353.0K$1.1M
Loss before income taxes$12.6M$7.5M$5.9M
Taxes on income-$14.0K$22.0K
Net loss and total comprehensive loss$12.6M$7.5M$5.9M
Equity holders of the Company$12.2M$6.3M$5.1M
Non-controlling interests$385.0K$1.2M$761.0K
Basic loss per ordinary share attributable to equity holders of the Company (in Dollars per share)$98.07$203.89$2,374.55
Diluted loss per ordinary share attributable to equity holders of the Company (in Dollars per share) (in Dollars per share)$98.07$203.89$2,374.55

Compare SciSparc with another company

Corporate structure

SciSparc sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of SciSparc

  • L.I.A. Pure Capital Ltd Filed SCHEDULE 13G/A on SciSparc, latest May 15, 2026 (2 filings since Jan 21, 2026)
  • Eli Zamir Filed SCHEDULE 13G on SciSparc, latest Mar 16, 2026 (2 filings since Dec 11, 2025)
  • Ronen Fatal Filed SCHEDULE 13G on SciSparc, latest Mar 16, 2026 (2 filings since Dec 11, 2025)
  • Nissim Daniel Filed SCHEDULE 13G/A on SciSparc, latest Mar 9, 2026 (2 filings since Dec 4, 2025)
  • YA II PN, Ltd. Filed SC 13G on SciSparc, latest Mar 6, 2024
  • Robert J. Eide Filed SC 13G/A on SciSparc, latest May 9, 2022
  • BIGGER CAPITAL FUND L P Filed SC 13G/A on SciSparc, latest Feb 11, 2022
  • SciSparc L3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What SciSparc reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$59.0K6 Dec 31, 2024$108.0K6 Dec 31, 2023−45.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.5M6 Dec 31, 2024$2.1M6 Dec 31, 2023−25.8%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$1.5M6 Dec 31, 2024$3.2M6 Dec 31, 2023−53.6%

Inventory

ItemLatestA year beforeChange
Inventory, total$113.0K6 Dec 31, 2024$742.0K6 Dec 31, 2023−84.8%

Leadership

Who has led SciSparc, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Oz Adler2026–now

Chief financial officer

  1. Oz Adler2026–now
  • Chief executive officerOz Adler Mar 18, 2026 to now13
  • Chief financial officerOz Adler Mar 18, 2026 to now13
Board members and other officers (8)

Former names

  • SciSparc Ltd./ADRFeb 1, 2021 to Aug 27, 20214
  • Therapix Biosciences Ltd.Jul 18, 2014 to Jan 28, 20214

Timeline

  1. Mar 18, 2026New chief executive Oz Adler becomes CEO13

Filings

353 filings to the SEC since October 2021: 7 annual reports, 19 insider forms, 11 large holders, 3 private raises, 313 other. The latest 20:

  1. Oct 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  2. Oct 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  3. Oct 7, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  4. Sep 30, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  5. Sep 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  6. Sep 2, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  7. Aug 31, 2026EFFECT EDGAR
  8. Aug 26, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  9. Aug 24, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  10. Aug 19, 2026F-3/A AMENDMENT NO. 1 TO FORM F-3 EDGAR
  11. Aug 19, 202620-F/A AMENDMENT NO. 1 TO FORM 20-F EDGAR
  12. Aug 18, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  13. Aug 12, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  14. Aug 5, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  15. Jul 31, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  16. Jul 29, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  17. Jul 15, 20266-K REPORT OF FOREIGN PRIVATE ISSUER EDGAR
  18. Jul 13, 20263/A EDGAR
  19. Jul 13, 20263/A EDGAR
  20. Jul 13, 20263/A EDGAR

The 353 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 1, 2026Shrem ItschakDirectorSale462$10.00$4.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Feb 25, 2025Raised $4.2 million in a private offering of debt Form D: 4 investors so far Form D
  2. Oct 11, 2023Raised $5 million in a private offering of securities Form D: 1 investor so far Form D
  3. Jun 1, 2022Raised $10 million in a private offering of equity Form D: 1 investor so far Form D

SEC filer profile

How SciSparc is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARSciSparc Ltd.2
  • CIK0001611746
  • Filer statusNon-accelerated filer not an emerging growth company; not a shell company5
  • Incorporated inIsrael5
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address20 Raul Wallenberg Street, Tower A, Tel Aviv, L3 69719162
  • Phone972-3-61031002
  • Shares outstanding365,444 shares as of Dec 31, 20255
  • AuditorBrightman Almagor Zohar & Co., Tel Aviv, Israel PCAOB ID 1197; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceJul 18, 20142
  • Filings604 in all: 6-K (328), CORRESP (44), UPLOAD (31), EFFECT (25), F-1/A (16), POS AM (11), 20-F (10), 3 (10)2
    All 45 form types

    425 (10), 3/A (9), F-4/A (9), 424B3 (8), F-3 (8), F-3/A (7), SCHEDULE 13G (7), 424B5 (6), F-1 (6), SC 13G (6), D (5), SC 13G/A (5), FWP (4), S-8 (4), SC 13D/A (4), 424B4 (3), 8-A12B (3), 144 (2), 20-F/A (2), CT ORDER (2), F-6 POS (2), SCHEDULE 13G/A (2), 25-NSE (1), 4 (1), 424B2 (1), 6-K/A (1), CERT (1), CERTNAS (1), DRS (1), DRS/A (1), DRSLTR (1), F-1MEF (1), F-4 (1), F-6 (1), NT 20-F (1), RW (1), SC 13D (1)

  • Latest filingsAnnual report (20-F) Apr 29, 2026

Securities registered for trading

ClassSymbolExchange
SPRCNasdaq

From the cover page of the 20-F filed Apr 29, 2026 (Section 12(b) of the Exchange Act).5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
    Company websiteSciSparc logo
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28